| pubmed-article:20039425 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0545661 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0243127 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C1623145 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C1609165 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C2745888 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0205412 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0439831 | lld:lifeskim |
| pubmed-article:20039425 | lifeskim:mentions | umls-concept:C0443331 | lld:lifeskim |
| pubmed-article:20039425 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20039425 | pubmed:dateCreated | 2010-1-13 | lld:pubmed |
| pubmed-article:20039425 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:abstractText | To investigate the effects of tocilizumab (TCZ) added to a stable dosage of methotrexate (MTX) on biochemical markers of bone and cartilage metabolism in patients in the multicenter double-blind, placebo-controlled OPTION (Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders) study who have moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to MTX. | lld:pubmed |
| pubmed-article:20039425 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20039425 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20039425 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20039425 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20039425 | pubmed:issn | 0004-3591 | lld:pubmed |
| pubmed-article:20039425 | pubmed:author | pubmed-author:GarneroPatric... | lld:pubmed |
| pubmed-article:20039425 | pubmed:author | pubmed-author:SmolenJosef... | lld:pubmed |
| pubmed-article:20039425 | pubmed:author | pubmed-author:ThompsonEliza... | lld:pubmed |
| pubmed-article:20039425 | pubmed:author | pubmed-author:WoodworthThas... | lld:pubmed |
| pubmed-article:20039425 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20039425 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:20039425 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20039425 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20039425 | pubmed:pagination | 33-43 | lld:pubmed |
| pubmed-article:20039425 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:meshHeading | pubmed-meshheading:20039425... | lld:pubmed |
| pubmed-article:20039425 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20039425 | pubmed:articleTitle | Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. | lld:pubmed |
| pubmed-article:20039425 | pubmed:affiliation | INSERM Unit 664, Lyon, France. patrickgarnero@free.fr | lld:pubmed |
| pubmed-article:20039425 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20039425 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:20039425 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20039425 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20039425 | lld:pubmed |
